Cysteine cathepsin activity regulation by glycosaminoglycans

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Novinec, Marko ^a   Lenarčič, Brigita ^a,b   Turk, Boris ^a,b,c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b JO EF STEFAN INSTITUTE   (Slovenia)

^c Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN K; CATHEPSIN S; CELL PROTEIN; CYSTEINE DERIVATIVE; GLYCOSAMINOGLYCAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PAPAIN; PEPTIDASE; CTSK PROTEIN, HUMAN; CYSTEINE;

ANTIGEN PRESENTATION; CATALYSIS; COLLAGEN DEGRADATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME RELEASE; ENZYME STABILITY; ENZYME STRUCTURE; HUMAN; LYSOSOME; NONHUMAN; PH; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; UPREGULATION; GENE; IMMUNOLOGY; METABOLISM;

ANTIGEN PRESENTATION; CATHEPSIN K; CYSTEINE; GENES, MHC CLASS II; GLYCOSAMINOGLYCANS; HUMANS; LYSOSOMES;

EID: 84920517066     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/309718     Document Type: Review

References (78)

1. N. D. Rawlings, A. J. Barrett, and A. Bateman, "MEROPS: the database of proteolytic enzymes, their substrates and inhibitors, " Nucleic Acids Research, vol. 40, no. 1, pp. D343-D350, 2012.
2. A. Rossi, Q. Deveraux, B. Turk, and A. Sali, "Comprehensive search for cysteine cathepsins in the human genome, " Biological Chemistry, vol. 385, no. 5, pp. 363-372, 2004.
3. V. Turk, V. Stoka, O. Vasiljeva et al. , "Cysteine cathepsins: from structure, function and regulation to new frontiers, " Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1824, no. 1, pp. 68-88, 2012.
4. M. Novinec and B. Lenarcic, "Papain-like peptidases: Structure, function, and evolution, " Biomolecular Concepts, vol. 4, no. 3, pp. 287-308, 2013.
5. O. Vasiljeva, T. Reinheckel, C. Peters, D. Turk, V. Turk, and B. Turk, "Emerging roles of cysteine cathepsins in disease and theirpotential as drug targets, " Current Pharmaceutical Design, vol. 13, no. 4, pp. 387-403, 2007.
6. I. Schechter and A. Berger, "On the size of the active site in proteases. I. Papain, " Biochemical and Biophysical Research Communications, vol. 27, no. 2, pp. 157-162, 1967.
7. D. Turk, G. Guncar, M. Podobnik, and B. Turk, "Revised definition of substrate binding sites of papain-like cysteine proteases, " Biological Chemistry, vol. 379, no. 2, pp. 137-147, 1998.
8. T. Inaoka, G. Bilbe, O. Ishibashi, K.-I. Tezuka, M. Kumegawa, and T. Kokubo, "Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone, " Biochemical and Biophysical Research Communications, vol. 206, no. 1, pp. 89-96, 1995.
9. W.-S. Hou, Z. Li, R. E. Gordon et al. , "Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation, " The American Journal of Pathology, vol. 159, no. 6, pp. 2167-2177, 2001.
10. M. Novinec and B. Lenarcic, "Cathepsin K: a unique collagenolytic cysteine peptidase, " Biological Chemistry, vol. 394, no. 9, pp. 1163-1179, 2013.
11. T. Zavasnik-Bergant and B. Turk, "Cysteine cathepsins in the immune response, " Tissue Antigens, vol. 67, no. 5, pp. 349-355, 2006.
12. D. Brömme, Z. Li, M. Barnes, and E. Mehler, "Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization, " Biochemistry, vol. 38, no. 8, pp. 2377-2385, 1999.
13. C. Stoeckle, C. Gouttefangeas, M. Hammer, E. Weber, A. Melms, and E. Tolosa, "Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs, " Experimental Hematology, vol. 37, no. 2, pp. 266-275, 2009.
14. A. Almond and J. K. Sheehan, "Glycosaminoglycan conformation: do aqueous molecular dynamics simulations agree with xray fiber diffraction?" Glycobiology, vol. 10, no. 3, pp. 329-338, 2000.
15. M. Cygler, J. Sivaraman, P. Grochulski, R. Coulombe, A. C. Storer, and J. S. Mort, "Structure of rat procathepsin B: model for inhibition of cysteine protease activity by the proregion, " Structure, vol. 4, no. 4, pp. 405-416, 1996.
16. R. Coulombe, P. Grochulski, J. Sivaraman, R. Ménard, J. S. Mort, and M. Cygler, "Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment, " EMBO Journal, vol. 15, no. 20, pp. 5492-5503, 1996.
17. J. Sivaraman, M. Lalumìere, R. Ménard, andM. Cygler, "Crystal structure of wild-type human procathepsin K, " Protein Science, vol. 8, no. 2, pp. 283-290, 1999.
18. D. Turk, M. Podobnik, R. Kuhelj, M. Dolinar, and V. Turk, "Crystal structures of human procathepsin B at 3. 2 and 3. 3 å resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide, " FEBS Letters, vol. 384, no. 3, pp. 211-214, 1996.
19. M. Podobnik, R. Kuhelj, V. Turk, andD. Turk, "Crystal structure of the wild-type human procathepsin B at 2. 5 å resolution reveals the native active site of a papain-like cysteine protease zymogen, " Journal of Molecular Biology, vol. 271, no. 5, pp. 774-788, 1997.
20. J. Rozman, J. Stojan, R. Kuhelj, V. Turk, and B. Turk, "Autocatalytic processing of recombinant human procathepsin B is a bimolecular process, " FEBS Letters, vol. 459, no. 3, pp. 358-362, 1999.
21. J. Rozman Pungercar, D. Caglic, M. Sajid et al. , "Autocatalytic processing of procathepsin B is triggered by proenzyme activity, " FEBS Journal, vol. 276, no. 3, pp. 660-668, 2009.
22. G. Dubin, "Proteinaceous cysteine protease inhibitors, " Cellular and Molecular Life Sciences, vol. 62, no. 6, pp. 653-669, 2005.
23. B. Turk, D. Turk, and G. S. Salvesen, "Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators, " Current Pharmaceutical Design, vol. 8, no. 18, pp. 1623-1637, 2002.
24. B. Turk, V. Turk, andD. Turk, "Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors, " Biological Chemistry, vol. 378, no. 3-4, pp. 141-150, 1997.
25. B. Lenarcic and T. Bevec, "Thyropins-new structurally related proteinase inhibitors, " The Biological Chemistry, vol. 379, no. 2, pp. 105-111, 1998.
26. J. L. Avila and J. Convit, "Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro, " Biochemical Journal, vol. 152, no. 1, pp. 57-64, 1975.
27. M. Fonović and B. Turk, "Cysteine cathepsins and extracellular matrix degradation, " Biochimica et Biophysica Acta-General Subjects, vol. 1840, no. 8, pp. 2560-2570, 2014.
28. K. Ishidoh and E. Kominami, "Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro, " Biochemical and Biophysical Research Communications, vol. 217, no. 2, pp. 624-631, 1995.
29. R. W. Mason and S. D. Massey, "Surface activation of procathepsin L, " Biochemical and Biophysical Research Communications, vol. 189, no. 3, pp. 1659-1666, 1992.
30. O. Vasiljeva, M. Dolinar, J. Rozman Pungercar, V. Turk, and B. Turk, "Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans, "The FEBS Letters, vol. 579, no. 5, pp. 1285-1290, 2005.
31. D. Caglic, J. Rozman Pungercar, G. Pejler, V. Turk, and B. Turk, "Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions, " The Journal of Biological Chemistry, vol. 282, no. 45, pp. 33076-33085, 2007.
32. C. Serveau, A. Boulangé, F. Lecaille, F. Gauthier, E. Authié, and G. Lalmanach, "Procongopain from Trypanosoma congolense is processed at basic pH: an unusual feature among cathepsin L-like cysteine proteases, " Biological Chemistry, vol. 384, no. 6, pp. 921-927, 2003.
33. J. Sage, F. Mallèvre, F. Barbarin-Costes et al. , "Binding of chondroitin 4-sulfate to cathepsin S regulates its enzymatic activity, " Biochemistry, vol. 52, no. 37, pp. 6487-6498, 2013.
34. D. Brömme, F. S. Nallaseth, and B. Turk, "Production and activation of recombinant papain-like cysteine proteases, " Methods, vol. 32, no. 2, pp. 199-206, 2004.
35. R. Kuhelj, M. Dolinar, J. Rozman Pungercar, and V. Turk, "The preparation of catalytically active human cathepsin B from its precursor expressed in Escherichia coli in the form of inclusion bodies, " European Journal of Biochemistry, vol. 229, no. 2, pp. 533-539, 1995.
36. G. Kopitar, M. Dolinar, B. Strukelj, J. Pungercar, and V. Turk, "Folding and activation of human procathepsin S from inclusion bodies produced in Escherichia coli, " European Journal of Biochemistry, vol. 236, no. 2, pp. 558-562, 1996.
37. J. Hallgren, D. Spillmann, and G. Pejler, "Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: formation of active tryptase monomers in the presence of low molecular weight heparin, " Journal of Biological Chemistry, vol. 276, no. 46, pp. 42774-42781, 2001.
38. M. Vanwildemeersch, A.-K. Olsson, E. Gottfridsson, L. Claesson-Welsh, U. Lindahl, andD. Spillmann, "The anti-angiogenicHis/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner, " The Journal of Biological Chemistry, vol. 281, no. 15, pp. 10298-10304, 2006.
39. M. Fairhead, S. M. Kelly, and C. F. van der Walle, "A heparin binding motif on the pro-domain of human procathepsin L mediates zymogen destabilization and activation, " Biochemical and Biophysical Research Communications, vol. 366, no. 3, pp. 862-867, 2008.
40. P. C. Almeida, I. L. Nantes, C. C. A. Rizzi et al. , "Cysteine proteinase activity regulation: a possible role of heparin and heparin-like glycosaminoglycans, " The Journal of Biological Chemistry, vol. 274, no. 43, pp. 30433-30438, 1999.
41. Z. Li, W. S. Hou, and D. Brömme, "Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates, " Biochemistry, vol. 39, no. 3, pp. 529-536, 2000.
42. B. D. Gelb, G.-P. Shi, H. A. Chapman, and R. J. Desnick, "Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency, " Science, vol. 273, no. 5279, pp. 1236-1239, 1996.
43. Z. Li, M. Kienetz, M. M. Cherney, M. N. G. James, and D. Brömme, "The crystal and molecular structures of a cathepsin K:chondroitin sulfate complex, " Journal of Molecular Biology, vol. 383, no. 1, pp. 78-91, 2008.
44. M. Novinec, L. Kovacic, B. Lenarcic, and A. Baici, "Conformational flexibility and allosteric regulation of cathepsin K, " Biochemical Journal, vol. 429, no. 2, pp. 379-389, 2010.
45. P. Saftig, E. Hunziker, O. Wehmeyer et al. , "Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-Kdeficient mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 23, pp. 13453-13458, 1998.
46. W. Kafienah, D. Brömme, D. J. Buttle, L. J. Croucher, and A. P. Hollander, "Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix, " Biochemical Journal, vol. 331, part 3, pp. 727-732, 1998.
47. P. Garnero, O. Borel, I. Byrjalsen et al. , "Thecollagenolytic activity of cathepsin K is unique among mammalian proteinases, " The Journal of Biological Chemistry, vol. 273, no. 48, pp. 32347-32352, 1998.
48. D. Brömme, K. Okamoto, B. B. Wang, and S. Biroc, "Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts: functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme, " Journal of Biological Chemistry, vol. 271, no. 4, pp. 2126-2132, 1996.
49. S. Boonen, E. Rosenberg, F. Claessens, D. Vanderschueren, and S. Papapoulos, "Inhibition of cathepsin K for treatment of osteoporosis, " CurrentOsteoporosis Reports, vol. 10, no. 1, pp. 73-79, 2012.
50. W. S. Hou, Z. Li, F. H. Büttner, E. Bartnik, and D. Brömme, "Cleavage site specificity of cathepsinKtoward cartilage proteoglycans and protease complex formation, " Biological Chemistry, vol. 384, no. 6, pp. 891-897, 2003.
51. V. M. Dejica, J. S. Mort, S. Laverty et al. , "Increased type II collagen cleavage by cathepsin K and collagenase activities with aging and osteoarthritis in human articular cartilage, " Arthritis Research andTherapy, vol. 14, no. 3, article R113, 2012.
52. V. M. Dejica, J. S. Mort, S. Laverty et al. , "Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage, " The American Journal of Pathology, vol. 173, no. 1, pp. 161169, 2008.
53. Z. Li, Y. Yasuda, W. Li et al. , "egulation of collagenase activities of human cathepsins by glycosaminoglycans, " The Journal of Biological Chemistry, vol. 279, no. 7, pp. 5470-5479, 2004.
54. Z. Li, W.-S. Hou, C. R. Escalante-Torres, B. D. Gelb, and D. Brömme, "Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate, " The Journal of Biological Chemistry, vol. 277, no. 32, pp. 28669-28676, 2002.
55. O. Borel, E. Gineyts, C. Bertholon, and P. Garnero, "CathepsinK preferentially solubilizes matured bonematrix, " Calcified Tissue International, vol. 91, no. 1, pp. 32-39, 2012.
56. B. Casu, M. Petitou, M. Provasoli, andP. Sinaÿ, "Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans, " Trends in Biochemical Sciences, vol. 13, no. 6, pp. 221-225, 1988.
57. P. C. Almeida, I. L. Nantes, J. R. Chagas et al. , "Cathepsin B activity regulation. Heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation, " Journal of Biological Chemistry, vol. 276, no. 2, pp. 944-951, 2001.
58. H. Kirschke, B. Wiederanders, D. Brömme, and A. Rinne, "Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins, " Biochemical Journal, vol. 264, no. 2, pp. 467-473, 1989.
59. T. Y. Nakagawa, W. H. Brissette, P. D. Lira et al. , "Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice, " Immunity, vol. 10, no. 2, pp. 207-217, 1999.
60. S. Guo-Ping, J. A. Villadangos, G. Dranoff et al. , "Cathepsin S required for normalMHC class II peptide loading and germinal center development, " Immunity, vol. 10, no. 2, pp. 197-206, 1999.
61. C. Driessen, R. A. R. Bryant, A. M. Lennon-Duménil et al. , "Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells, " Journal of Cell Biology, vol. 147, no. 4, pp. 775-790, 1999.
62. M. Novinec, M. Korenc, A. Caflisch, R. Ranganathan, B. Lenarcic, and A. Baici, "A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods, " Nature Communications, vol. 5, Article ID3287, 2014.
63. D. Musil, D. Zucic, D. Turk et al. , "The refined 2. 15 å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity, " EMBO Journal, vol. 10, no. 9, pp. 2321-2330, 1991.
64. M. M. Mohamed and B. F. Sloane, "Cysteine cathepsins: multifunctional enzymes in cancer, " Nature Reviews Cancer, vol. 6, no. 10, pp. 764-775, 2006.
65. A. Baici, A. Lang, R. Zwicky, and K. Müntener, "Cathepsin B in osteoarthritis: uncontrolled proteolysis in the wrong place, " Seminars in Arthritis and Rheumatism, vol. 34, no. 2, pp. 24-28, 2004.
66. D. Cavallo-Medved, J. Mai, J. Dosescu, M. Sameni, and B. F. Sloane, "Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells, " Journal of Cell Science, vol. 118, no. 7, pp. 1493-1503, 2005.
67. D. Cavallo-Medved, D. Rudy, G. Blum, M. Bogyo, D. Caglic, and B. F. Sloane, "Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation, " Experimental Cell Research, vol. 315, no. 7, pp. 1234-1246, 2009.
68. T. T. Lah, M. R. Buck, K. V. Honn et al. , "Degradation of laminin by human tumor cathepsin B, " Clinical and Experimental Metastasis, vol. 7, no. 4, pp. 461-468, 1989.
69. M. R. Buck, D. G. Karustis, N. A. Day, K. V. Honn, and B. F. Sloane, "Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues, " Biochemical Journal, vol. 282, no. 1, pp. 273-278, 1992.
70. V. Hook, T. Toneff, M. Bogyo et al. , "Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimers disease, " Biological Chemistry, vol. 386, no. 12, pp. 931-940, 2005.
71. C. Wang, B. Sun, Y. Zhou, A. Grubb, and L. Gan, "Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein, "The Journal of Biological Chemistry, vol. 287, no. 47, pp. 39834-39841, 2012.
72. B. Sun, Y. Zhou, B. Halabisky et al. , "Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimers disease, " Neuron, vol. 60, no. 2, pp. 247-257, 2008.
73. M. G. S. Costa, P. R. Batista, C. S. Shida, C. H. Robert, P. M. Bisch, and P. G. Pascutti, "How does heparin prevent the pH inactivation of cathepsin B Allosteric mechanism elucidated by docking and molecular dynamics, " BMC Genomics, vol. 11, supplement 5, article S5, 2010.
74. T. F. R. Costa, F. C. G. D. Reis, and A. P. C. A. Lima, "Substrate inhibition and allosteric regulation by heparan sulfate of Trypanosoma brucei cathepsin L, " Biochimica et Biophysica Acta, vol. 1824, no. 3, pp. 493-501, 2012.
75. A. P. Lima, P. C. Almeida, I. L. Tersariol et al. , "Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain, "The Journal of Biological Chemistry, vol. 277, no. 8, pp. 5875-5881, 2002.
76. W. A. S. Judice, M. A. Manfredi, G. P. Souza et al. , "Heparin modulates the endopeptidase activity of Leishmania mexicana cysteine protease cathepsin L-like rCPB2. 8, " PLoS ONE, vol. 8, no. 11, Article ID e80153, 2013.
77. J. Y. Gauthier, N. Chauret, W. Cromlish et al. , "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K, " Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 3, pp. 923-928, 2008.
78. K. Lippuner, "The future of osteoporosis treatment-a research update, " SwissMedicalWeekly, vol. 142, Article IDw13624, 2012.